Modern Approach to Fabry Disease Diagnosis and Management in Children

Fabry disease (FD), or Andersen-Fabry disease, is a rare hereditary lysosomal disease (sphingolipids storage disease) characterized by progressive multisystem involvement. The major symptoms among children are neuropathic pain / acroparesthesia, angiokeratomas, hypo- or anhidrosis, vortex keratopathy. Biochemical tests, molecular genetic testing, and family screening play crucial role in the diagnosis of the disease. Specific pathogenetic treatment of FD includes enzyme replacement therapy (ERT) with recombinant medications of the lysosomal enzyme -galactosidase A. ERT initiation before the development of severe organs and systems’ damage contributes to its higher efficacy. This article covers various aspects of pathogenesis, clinical picture features in childhood, modern methods of diagnosis and management of FD according to literature data.

1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010; 5: 30. doi: https://doi.org/10.1186/1750-1172-5-30

2. Hopkin RJ, Bissler J, Banikazemi M, et al. Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatr Res. 2008;64(5):550–555. doi: https://doi.org/10.1203/PDR.0b013e318183f132

3. Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(2): 284–293. doi: https://doi.org/10.1016/j.kint.2016.10.004

4. Karovaikina E, Moiseev A, Bulanov N, et al. Screening, diagnosis and treatment of Fabry disease. Klinicheskaya farmakologiya i terapiya. 2019;28(3):68–74. (In Russ). doi: https://doi.org/10.32756/0869-5490-2019-3-68-74

5. Ouyang Y, Chen B, Pan X, et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease. Exp Ther Med. 2018;15(4):3733-42. doi: https://doi.org/10.3892/etm.2018.5889.

6. Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1-2):57–61. doi: https://doi.org/10.1016/j.ymgme.2016.10.006

7. Maruyama H, Miyata K, Mikame M, et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med. 2019;21(1):44–52. doi: https://doi.org/10.1038/gim.2018.31

8. Maron MS, Xin W, Sims KB, et al. Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy. Am J Med. 2018;131(2):200.e1–200.e8. doi: https://doi.org/10.1016/j.amjmed.2017.09.010

9. Newman DB, Miranda WR, Matern D, et al. Cost efficacy of α-galactosidase A enzyme screening for Fabry disease. Mayo Clin Proc. 2019;94(1):84–88. doi: https://doi.org/10.1016/j.mayocp.2018.08.009

10. Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41(1): 78–81. doi: https://doi.org/10.1161/STROKEAHA.109.558320

11. Rolfs A, Buttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499):1794–1796. doi: https://doi.org/10.1016/S0140-6736(05)67635-0

12. Reisin RC, Mazziotti J, Cejas LL, et al. Prevalence of Fabry disease in young patients with stroke in Argentina. J Stroke Cerebrovasc Dis. 2018;27(3):575–582. doi: https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.045

13. Song X, Xue S, Zhao J, Wu J. Screening for Fabry’s disease in young patients with ischemic stroke in a Chinese population. Int J Neurosci. 2017;127(4):350–355. doi: https://doi.org/10.3109/00207454.2016.1166107

14. Laney DA, Fernh PM. Diagnosis of Fabry disease via analysis of family history. J Genet Counsel. 2008;17(1):79–83. doi: https://doi.org/10.1007/s10897-007-9128-x

15. Bolezn’ Fabri: Сlinical guidelines. Association of Medical Genetics; Union of Pediatricians of Russia. 2019. 53 p. (In Russ).

16. Moore DF, Goldin E, Gelderman MP, et al. Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease. Acta Paediatr. 2008;97(457): 48–52. doi: https://doi.org/10.1111/j.1651-2227.2008.00654.x

17. De Francesco PN, Mucci JM, Ceci R, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93–99. doi: https://doi.org/10.1016/j.ymgme.2013.02.003

18. Fujinaga S, Murakami H, Kubota M, et al. Is there a pathogenic association between Fabry’s disease and IgA nephropathy? Clin Nephrol Case Stud. 2013;1:14–17. doi: https://doi.org/10.5414/CNCS107994

19. Martinez P, Aggio M, Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J Inherit Metab Dis. 2007;30(3): 365–369. doi: https://doi.org/10.1007/s10545-007-0513-2

20. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372–373. doi: https://doi.org/10.1038/190372a0

21. Kotov AS, Firsov KV. Neurological manifestations of Fabry disease in children and adolescents. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology. 2017;12(3):51–57. (In Russ). doi: https://doi.org/10.17650/2073-8803-2017-12-3-51-57

22. Yoo HW. Fabry disease: current treatment and future perspective. J Genet Med. 2023;20(1):6-14. doi: https://doi.org/10.5734/JGM.2023.20.1.6

23. McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79(5):543–554. doi: https://doi.org/10.1007/s40265-019-01090-4

24. Voitenkov VB, Ekusheva EV. Pain syndrome in Fabry disease: semiotics, diagnostics and treatment. RMJ. 2019;(9):50–54. (In Russ).

25. Moiseev SV, Ismailova DS, Moiseev AS, et al. Cornea verticillata in Fabry disease. Therapeutic Archive. 2018;90(12): 17–22. (In Russ). doi: https://doi.org/10.26442/00403660.2018.12.000003

26. Gambini G, Scartozzi L, Giannuzzi F, et al. Ophthalmic anifestations in Fabry Disease: Updated Review. J Pers Med. 2023;13(6):904. doi: https://doi.org/10.3390/jpm13060904

27. Cordeiro CA, Oréfice F, Lasmar EP, et al. Cornea verticillata — a clinical marker of Fabry disease: case report. Arq Bras Oftalmol. 2007;70(4):701–705. doi: https://doi.org/10.1590/s0004-27492007000400024

28. Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767–776. doi: https://doi.org/10.1053/j.ajkd.2007.12.032

29. Moiseev SV, Mershina EA, Sinitsin VE, et al. Cardiac magnetic resonance imaging in patients with Fabry disease. Klinicheskaya farmakologiya i terapiya. 2017;26(3):13–20. (In Russ).

30. Cortes-Saladelafont E, Fernandez-Martin J, Ortolano S. Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int J Mol Sci. 2023;24(6):5246. doi: https://doi.org/10.3390/ijms24065246

31. Moiseev AS, Tao EA, Bulanov NM, et al. Central nervous system involvement in Fabry disease. Klinicheskaya farmakologiya i terapiya. 2022;31(1):32–38. (In Russ). doi: https://doi.org/10.32756/0869-5490-2022-1-32-3

32. Moiseev SV, Novikov PI, Bulanov NM, et al. Fabry disease in rheumatology practice. Klinicheskaya farmakologiya i terapiya. 2018;27(1):39–45 (In Russ).

33. Manna R, Cauda R, Feriozzi S, et al. Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. Intern Emerg Med. 2017;12(7):1059–1067. doi: https://doi.org/10.1007/s11739- 017-1704-y

34. Sakuraba H, Togawa T, Tsukimura T, et al. Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22(4):843–849. doi: https://doi.org/10.1007/s10157-017-1525-3

35. Polo G, Burlina A, Ranieri E, et al. Plasma and dried blood spot lysosphingolipids for the diagnosis of different sphingolipidoses: a comparative study. Clin Chem Lab Med. 2019;57(12): 1863–1874. doi: https://doi.org/10.1515/cclm-2018-1301

36. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–427. doi: https://doi.org/ 10.1016/j.ymgme.2018.02.014

37. Biegstraaten M, Arngrнmsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. doi: https://doi.org/10.1186/s13023-015-0253-6

38. Instructions for medical use of the drug Replagal. No. ЛСР-00551/09. (In Russ).

39. Instructions for medical use of the drug Fabrazyme. No. ЛСР-003334/09 (In Russ).

40. Hwang S, Lee BH, Kim WS, et al. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease. Medicine (Baltimore). 2022;101(37):e30345. doi: https://doi.org/10.1097/MD.0000000000030345

41. Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. doi: https://doi.org/10.2174/1381612826666200317142412

42. Germain DP, Arad M, Burlina A, et al. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease — A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):224–235. doi: https://doi.org/10.1016/j.ymgme.2018.09.007

43. Hopkin RJ, Cabrera G, Charrow J, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry. Mol Genet Metab. 2016;119(1-2): 151–159. doi: https://doi.org/10.1016/j.ymgme.2016.06.007

44. Riccio E, Pisani A. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: switch studies data following agalsidase beta shortage. Clin Genet. 2023;103(3): 371–376. doi: https://doi.org/10.1111/cge.14266

45. Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635–645. doi: https://doi.org/ 10.1007/s40265-021-01486-1

46. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137 (1-2):49–61. doi: https://doi.org/10.1016/j.ymgme.2022.07.010

47. Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568–576. doi: https://doi.org/10.1111/cns.12542

48. Mehta A, West ML. Therapeutic goals in the treatment of Fabry disease. Genet Med. 2010;12(11):713–720. doi: https://doi.org/10.1097/GIM.0b013e3181f6e676

49. Laney DA, Bennett RL, Clarke V, et al. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2013;22(5):555–564. doi: https://doi.org/10.1007/s10897-013-9613-3